Illuminating the path to better health through genetic insights

40th Annual J.P. Morgan Health Care Conference
January 11, 2022

Paul J. Diaz
President and CEO
Myriad Genetics
Forward looking statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company.

These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual and transition reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements. Market opportunity figures and growth rates used in this presentation are estimates based on Company and third-party industry research.

NON-GAAP FINANCIAL MEASURES

In this presentation, the Company’s financial results and financial guidance are provided in accordance with accounting principles generally accepted in the United States (GAAP) and using certain non-GAAP financial measures. Management believes that presentation of operating results using non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company’s core operating results and comparison of operating results across reporting periods. Management also uses non-GAAP financial measures to establish budgets and to manage the Company’s business. A reconciliation of the GAAP to non-GAAP financial results is provided under the investor section of Myriad’s corporate website at www.myriad.com.
Who we are, what we do, and why it matters

Illuminating the path to better health through genetic insights.

Our purpose-led Mission

We advance health and wellbeing for all, empowering every individual by revealing the answers inside each of us.

Our Vision

As a leader in genetic testing and precision medicine, we provide insights that help people take control of their health, and enable healthcare providers to better detect, treat and prevent disease.

Health. Illuminated.
Empowering patients with answers and insights for better health

What’s my risk of breast cancer?

3 million MyRisk™ patients

How can I learn more about my baby’s health during pregnancy?

2.1 million Prequel® + Foresight® patients

Why isn’t my antidepressant working?

1.7 million GeneSight® patients

How can I beat this cancerous tumor?

150,000 MyChoice®CDx + Prolaris® patients
# Three focused businesses primed for growth

<table>
<thead>
<tr>
<th>Business</th>
<th>Mental Health</th>
<th>Women’s Health</th>
<th>Oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helping physicians understand how genetic alterations impact patient response to antidepressants and other drugs.</td>
<td>Serving women of all ancestries, assessing risk of cancer and offering prenatal testing solutions.</td>
<td>Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs &amp; treatments.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Market*</th>
<th>$5B U.S. Market</th>
<th>$4B U.S. Market</th>
<th>$4B U.S. Market</th>
</tr>
</thead>
<tbody>
<tr>
<td>Growing 15%</td>
<td>Growing 10%</td>
<td>Growing 8%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Products</th>
<th>GeneSight*</th>
<th>MyRisk®</th>
<th>MyRisk®</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mental Health Medication Test</td>
<td>Hereditary Cancer Test</td>
<td>MyChoice®CDx Myriad HRD Companion Diagnostic Test</td>
<td></td>
</tr>
</tbody>
</table>

| Operating Results | Q3 ‘21 volume: 72,110 | Q3 ‘21 revenue: $24.1M | Q3 ‘21 volume: 110,141 | Q3 ‘21 revenue: $59.1M | Q3 ‘21 volume: 47,829 | Q3 ‘21 revenue: $76.8M |

* Based upon company and industry research
Transformation and growth strategy
Strategic priorities

A trusted, differentiated partner with specialized expertise

Innovation that improves clinical outcomes, ease of use, and access
Developing and enhancing best-in-class products to support growth, improve patient and provider experience and reach more patients of all backgrounds

Enterprise capabilities to accelerate growth and scale to market opportunity
Investing in tech-enabled commercial tools to drive engagement, improve revenue cycle management, reduce complexity and cost

Focus on execution and delivery of consistent results
Disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability
Executing our transformation plan, on track to accelerate growth

1. **Reset the base**
   - Launched transformation plan
   - Redefined brand and mission
   - Developed new commercial model
   - Eliminated all outstanding debt
   - Recovered test volumes

2. **Elevate current portfolio to full potential**
   - Debuted new brand and marketing strategy
   - Reinvested and restructured sales force
   - Enhanced reimbursement and revenue cycle management
   - Initiated steps to fulfill commitment to ESG, including diversity, equity and inclusion
   - Launched new products and offerings
     - MyRisk™ with RiskScore® for all ancestries
     - GeneSight® Psychotropic
     - MyGeneHistory™ 3.0

3. **Accelerate growth**
   - Build commercial capabilities to support new products and offerings
   - Launch new enterprise commercial model
   - Further develop direct-to-consumer channels
   - Launch unified ordering portal
   - Roll out ‘Lab of the Future’ – new sequencing technologies
   - New investments in tech, IS infrastructure
   - Strategic partnerships and acquisitions
Mental Health
Addressing the U.S. mental health crisis and need for medication testing

Helping physicians understand how genetic alterations impact patient response to antidepressants and other drugs.

GeneSight®
Mental Health Medication Test

Elevating GeneSight® to full potential

- GeneSight volumes growing in key provider segments, including primary care, nurse practitioners
- 95% of providers order through online portal
- 10-15% of business originates from digital marketing efforts
- 30% of kits are home-based tests
- Exploring new partnerships in neurology to develop tests for early detection and treatment of Alzheimer's

Mark Verratti – President
Q3 ’21 revenue: $24.1M
1.7M+ people tested to date
7 clinical studies published

$5B U.S. Market | Growing 15%

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com
11 January 2022
Commercial model driving lead generation, conversion in mental health

Inside Sales cultivates broader base of leads – frees sales force to serve high potential accounts

Field Sales works high potential, high revenue clinical leads
Commercial model continues to drive new users

Key drivers

- Virtual patient testing capabilities
- Online ordering
- GeneSight@Home
- Text and email messaging
- Comprehensive mental health test, including ADHD

Volume

Growing at >20% CAGR

3Q 20 | 4Q 20 | 1Q 21 | 2Q 21 | 3Q 21

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com
Women’s Health
Serving healthcare providers and the women who rely on them

Leading health and wellness with best-in-class genetic insights for women of all ancestries, assessing risk of cancer and offering prenatal testing solutions.

**Women’s Health**

**Market**

- **$4B U.S. Market**  |  **Growing 10%**

**Business**

- Melissa Gonzales – President
  Q3 ’21 revenue: $59.1M

  Working to launch a version of GeneSight® test for women with postpartum depression

---

**2021 Launch**

**MyRisk™**

Hereditary Cancer Test

- 5-year and lifetime breast cancer risk assessment
  - Only test of its kind for women of all ancestries
  - 56% of women qualify for medical management (vs. 10% with standard hereditary cancer test)

**FirstGene™**

Combination noninvasive prenatal screening + carrier screening

- 2023 Launch

- Only 1 out of 3 patients undergo carrier screening and NIPS during a pregnancy

- Unmet need to simplify process

- Comprehensive assessment with a single blood draw

---

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com

11 January 2022
Key product enhancement – personalized breast cancer risk for all women

New in 2021

- Only Myriad provides genetically-informed breast cancer risk assessment as part of a comprehensive panel, with equity in care for all patients
- Closing the gap between women who meet NCCN guidelines for MyRisk and do not have European ancestry with those who do

The first and only hereditary cancer test incorporating genetic markers for patients without a high-risk gene mutation

RiskScore®

35 hereditary cancer genes + Personal & family history + Breast cancer genetic risk markers + Ancestry genetic markers = RiskScore®
Combined prenatal test simplifies and advances prenatal patient care

Advantages
- Early insight into recessive disease status
- Eliminates unnecessary amniocentesis
- Increased sensitivity for all pregnancies
- Single maternal (no paternal) blood draw

Simplified Workflow

New - early 2023
FirstGene™
Comprehensive Prenatal Screen

Advantages

- Early insight into recessive disease status
- Eliminates unnecessary amniocentesis
- Increased sensitivity for all pregnancies
- Single maternal (no paternal) blood draw

Current

<table>
<thead>
<tr>
<th>Basic NIPS</th>
<th>Parental CS</th>
<th>Fetal recessive status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prequel*</td>
<td>Foresight*</td>
<td></td>
</tr>
<tr>
<td>Prenatal Screen</td>
<td>Carrier Screen</td>
<td></td>
</tr>
<tr>
<td>Maternal cfDNA</td>
<td>Maternal DNA</td>
<td>Not easily available with existing screening modalities</td>
</tr>
</tbody>
</table>

Future

FirstGene™ Comprehensive Prenatal Screen

- Power of Prequel
- Power of Foresight
- Deeper fetal insights

Maternal cfDNA

* Scheduled for launch in 2023. Diagnostic test like amniocentesis still recommended as follow-up confirmation for a positive result. FirstGene provides insight into recessive status of the fetus in a screening modality.
Providing answers that guide cancer treatment decisions

**Oncology**

Genetic testing for cancer patients and companion diagnostic tests that work with corresponding drugs and treatments.

**Market**

$4B U.S. Market | Growing 8%

**Business**

Faith Zaslavsky – President Q3 ‘21 revenue: $76.8M

- Combining strength in germline/hereditary cancer testing and companion diagnostics
- Expanding across care continuum with suite of offerings in one convenient, differentiated experience that provides oncologists with the single service they want
- Building market-leading companion diagnostics portfolio – extending beyond ovarian to breast, prostate, and pancreatic cancer
- Plan to expand portfolio into Liquid Bx treatment and Liquid Bx MRD

**MyRisk®** Hereditary Cancer Test
**MyChoice® CDx** Myriad HRD Companion Diagnostic Test
**EndoPredict®** Breast Cancer Prognostic Test
**Precise™ Tumor** Molecular Profile Test
**BRACAnalysis CDx®** Germline Companion Diagnostic Test
**Prolaris®** Prostate Cancer Prognostic Test
Molecular diagnostics across the continuum of cancer care

MyRisk® Hereditary Cancer Test

New RiskScore®

High Risk Screening

Surgical Decisions

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

Precise™ Tumor
Molecular Profile Test

Precise Liquid Bx
Therapeutic Selection

BRACAnalysis CDx®
Germline Companion Diagnostic Test

Precise Liquid Bx
MRD

EndoPredict™
Breast Cancer Prognostic Test

Measurable Residual Disease

Working to expand portfolio into Liquid Bx therapy selection and Liquid Bx MRD

Monitoring Recurrence

Planned Product Expansion:
A differentiated, comprehensive solution for advanced precision oncology

New Precise™ Oncology Solutions

MyRisk™ Hereditary Cancer Test +

MyChoice® CDx Myriad HRD Companion Diagnostic Test +

New Precise™ Tumor Molecular Profile Test

Launching this quarter

Helping providers determine the best treatment plan – clear, integrated, personalized

• Partnering with Intermountain Healthcare and Illumina to become the only lab with combination of:
  - World-class germline testing (MyRisk™ / BRACAnalysis CDx®)
  - HRD “Gold Standard” (MyChoice® CDx)
  - Best-in-class Comprehensive Genetic Tumor Panel (Illumina’s TSO500 / Precise™ Tumor)

• Helping patients understand cancer genetics and if it affects their family
Companion diagnostics
Rapidly growing ~ $100M CDx business positioned for market expansion

MyChoice® CDx
Myriad HRD Companion Diagnostic Test

- Market leading expertise with BRACAnalysis CDx and novel, patented homologous DNA-repair deficiency (HRD) test, MyChoice CDx
- MyChoice CDx recently approved by US, European and Japanese regulatory agencies to predict response to PARP-inhibitors (PARPi’s) in ovarian cancer
- Expanding MyChoice CDx into indications beyond ovarian cancers:
  - Currently being tested in more than a dozen clinical trials, including patients with breast, prostate, pancreatic and other cancer types
  - Approval to use MyChoice CDx in breast, prostate and pancreatic cancer represents an opportunity to expand MyChoice market by ~8X

| Total addressable market opportunity | Ovarian Cancer $300M / year | Breast, Prostate, Pancreatic Cancers $2B / year |

CDx Revenue (Q3 trailing 4 quarters in $M)
- BRACAnalysis CDx: $48
- MyChoice CDx: $42

US/International Pharma (R&D)
Simplifying treatment decisions for men with prostate cancer

Key Growth Drivers

• ~250K men diagnosed with prostate cancer / year, 2nd most common cancer
• $900M total addressable market – only 25% penetrated
• Medicare and commercial coverage expanded to ALL risk patients with localized prostate cancer
• Myriad is the only lab offering both germline testing (MyRisk, BRACAnalysis CDx) + biomarker analysis of tumor (Prolaris)

Operating Results

25% Test volume growth in Q3 2021 YOY

2X Revenue growth in Q3 2021, from ~$6.4M to ~$12.9M

Market leading tumor mRNA expression test that directly measures tumor cell growth – helps identify how prostate cancer is behaving and what treatment options will be most effective in fighting it.
## Roadmap to expanding Myriad’s oncology portfolio

<table>
<thead>
<tr>
<th>2022</th>
<th>2023</th>
<th>2024 - 2025</th>
<th>Incremental Annual Market Opportunity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Combine commercial strength, clinical core and collaborations</td>
<td>Launching Precise Oncology Solutions &amp; Precise Tumor</td>
<td></td>
<td>$1B</td>
</tr>
<tr>
<td>Advancing partnership negotiations to enter liquid market</td>
<td>Launch Precise LBx Therapy Selection</td>
<td></td>
<td>$2B - $3B</td>
</tr>
<tr>
<td>Proven technology, on-going clinical trials and expansion of pharma partner relationships</td>
<td>Launch MyChoice CDx for multiple cancer types</td>
<td></td>
<td>$1B</td>
</tr>
<tr>
<td>Partnership on LBx, existing whole exome and Amplify™ technologies will enable and differentiate Myriad’s MRD offering</td>
<td>Launch Precise MRD</td>
<td></td>
<td>$5B - $20B</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>Total $9B - $25B</td>
</tr>
</tbody>
</table>

11 January 2022
Accelerating new commercial capabilities
Scaling our enterprise commercial and tech capabilities

- 800 sales, medical, and customer service team members
- 95% of payers cover Myriad testing in network
- 60,000+ active ordering clinicians
- $50M+ tech investment to drive volume and improve customer engagement
- $12M+ enterprise commercial and marketing capabilities

<table>
<thead>
<tr>
<th>Competitive intelligence and market planning</th>
<th>Product/channel management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brand management and marketing</td>
<td>Tech-enabled customer experience</td>
</tr>
<tr>
<td>Sales operations and performance management</td>
<td>600+ EMR integrations and new unified ordering portal</td>
</tr>
</tbody>
</table>

High potential, innovative products
Investing in direct-to-consumer demand generation – promising early results

3-year goal
>1 million qualified consumer leads for multiple products through patient-initiated testing

Encounter
Sees targeted ads

Consider
Visits website to see if testing is appropriate for them

Inquire
Initiates genetic testing

Tests
Order reviewed and placed by healthcare provider

Q3 '21 results: Qualified lead conversion up > 28% and growing through telemedicine + direct kit shipment
Customized end-to-end solutions for easy customer experience

**Myriad Complete™**

Suite of services and workflow solutions

- Simplifies genetic testing through patient and provider support at every step
- Seamlessly integrates into clinic workflow
- Saves time and streamlines workflow
- Customizable based on clinic needs

1. **Patient Identification**
   - based on medical society guidelines
   - Digital screening with MyGeneHistory™
   - Radiology information systems
   - Mammography info systems

2. **Pre-test Education**
   - with Certified Genetic Counselor
   - Individualized education
   - Follow-up documentation

3. **Ordering**
   - Online portal
   - Virtual orders
   - EMR Integrations
   - Phlebotomy

4. **Affordability**
   - Personalized cost estimates
   - In-network with 95% of payors
   - Financial assistance for those who qualify

5. **Results**
   - with MyRisk™ Management Tool
   - Personalized Risk assessment
   - Online portal
   - EMR integration

6. **Post-test consults**
   - with certified Genetic Counselor
   - Individualized discussion of results
   - Detailed summary notes

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com
Stabilizing business and driving sustainable growth
Myriad continues to stabilize business and improve operating and financial results

Financial highlights

- Restored same-store growth
- Improved gross margins and profitability through disciplined expense controls
- Returned $400M to balance sheet through divestitures and improved revenue cycle management
- Expect to enter 2022 with ~$400M cash and no debt

Q3’21 YoY volume: +20%  Q3’21 YoY revenue: +27%

*excludes divested assets
Expect organic revenue growth to accelerate in 2022 going into 2023 through improved sales and marketing execution, product and technology innovation.

- **Mental Health**
  - GeneSight® momentum
  - FirstGene™ – Combined Prequel and Foresight product launch
  - Expanded medical association guidelines

- **Women’s Health**
  - +4-5%

- **Oncology**
  - +3-4%
  - Precise™ oncology solution launch
  - MyChoice™ CDx expansion
  - Prolaris® momentum

- **MyRisk stabilization**
  - RiskScore for all ancestries
  - Streamlined ordering and billing services, EMR integration
  - Direct-to-consumer channel

- **Upside**
  - 9-12% estimated organic revenue growth ‘22-’24
  - +2-3%

  - Accelerating growth rate in ’24+

- **New oncology solutions including liquid biopsy and MRD**
- **Women’s Health product and channel expansion**
- **Companion diagnostics expansion of indications and pharma partnerships**
- **M&A / strategic partnerships**
# Myriad Genetics 2022 financial guidance

<table>
<thead>
<tr>
<th></th>
<th>Guidance</th>
<th>Key Assumptions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue*</td>
<td>$670-$700</td>
<td>8% - 13% growth from 2021 baseline that excludes divested assets and positive cash collections from prior period orders</td>
</tr>
<tr>
<td>Gross Margin %</td>
<td>70% - 72%</td>
<td>Gross margins impacted by benefits from lab efficiencies and automations offset by increasing supply costs &amp; wage inflation</td>
</tr>
<tr>
<td>Adjusted Operating Expenses*</td>
<td>$470 - $480</td>
<td>Operating expenses impacted by investments in technology, commercial tools, R&amp;D as well as inflationary pressures</td>
</tr>
<tr>
<td>Adjusted EPS</td>
<td>$0.00 - $0.20</td>
<td></td>
</tr>
</tbody>
</table>

*In millions
Investment considerations: Myriad strengths and strategic advantages

Leader in genetic testing and precision medicine

- Transformation and growth strategy on track
- Broad and growing commercial capabilities with 60K healthcare providers ordering Myriad products across Women’s Health, Oncology and Mental Health
- Commercial platform with market-leading breadth of payer relationships and revenue cycle management capabilities
- Trusted, differentiated healthcare partner with specialized expertise
Appendix
– Third quarter 2021 operating and financial results
Third quarter operating and financial results were strong, despite COVID-19 headwinds and typical seasonal softness

1. Total revenue of $167.3M increased 15% YOY
   Excluding the impact of the divested Vectra, RBM and myPath businesses, quarterly revenue increased 27% YOY

2. Diagnostic test volumes of 252,000 increased 15% YOY.
   Stability in ASPs for past four quarters, excluding impact of out-of-period collections

3. GAAP total operating expenses were $199.4 million; adjusted total operating expenses decreased $1.6 million sequentially to $121.5 million

4. GAAP operating loss in the quarter was ($79.9) million; adjusted operating loss was ($1.4) million

5. GAAP EPS of $0.30; Adjusted EPS were ($0.02), and we remain on track to return to profitability in 2022

Closed divestiture of Myriad Autoimmune (Vectra) business
Paid down revolving credit facility - $413.6 million cash, cash equivalents and investments
# Consolidated quarterly highlights

## Revenue, adjusted gross margin, adjusted operating income, adjusted EPS

<table>
<thead>
<tr>
<th>In millions</th>
<th>Quarter ended</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>September 2021</td>
</tr>
<tr>
<td>Revenue</td>
<td>$167.3</td>
</tr>
<tr>
<td>Sequential change</td>
<td>(12%)</td>
</tr>
<tr>
<td>Adjusted gross margin</td>
<td>71.7%</td>
</tr>
<tr>
<td>Sequential change</td>
<td>-40 bp</td>
</tr>
<tr>
<td>Adjusted op income (loss)</td>
<td>($1.4)</td>
</tr>
<tr>
<td>Sequential change</td>
<td>($14.9)</td>
</tr>
<tr>
<td>Adjusted op income (loss)</td>
<td>($0.02)</td>
</tr>
<tr>
<td>Sequential change</td>
<td>($0.14)</td>
</tr>
<tr>
<td>Revenue from prior period collections</td>
<td>$8</td>
</tr>
</tbody>
</table>
## Third quarter 2021 — revenue by product

### Three months ended September 30

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>In millions</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hereditary cancer</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women’s Health</td>
<td>$35.5</td>
<td>$39.2</td>
<td>(1%)</td>
</tr>
<tr>
<td>Oncology</td>
<td>$43.9</td>
<td>$41.3</td>
<td></td>
</tr>
<tr>
<td>Mental Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$79.4</td>
<td>$80.5</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor profiling</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women’s Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prenatal</strong></td>
<td>$23.6</td>
<td>$16.6</td>
<td>42%</td>
</tr>
<tr>
<td><strong>Pharmacogenomics</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women’s Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$24.1</td>
<td>$11.9</td>
<td>103%</td>
</tr>
<tr>
<td><strong>Autoimmune</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women’s Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$7.3</td>
<td>$9.1</td>
<td>(20%)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Women’s Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td>$0.6</td>
<td>(100%)</td>
</tr>
<tr>
<td><strong>Total molecular diagnostic revenue</strong></td>
<td>$59.1</td>
<td>$55.8</td>
<td>23%</td>
</tr>
<tr>
<td><strong>Pharmaceutical and clinical service revenue</strong></td>
<td></td>
<td></td>
<td>(100%)</td>
</tr>
<tr>
<td>Women’s Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental Health</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>$24.1</td>
<td>$9.5</td>
<td></td>
</tr>
<tr>
<td><strong>Total revenue</strong></td>
<td>$59.1</td>
<td>$55.8</td>
<td>15%</td>
</tr>
</tbody>
</table>

©2022 Myriad Genetics, Inc. All rights reserved. www.Myriad.com

11 January 2022
### Revenue and test performance

#### Year-over-year change September 2020-September 2021

<table>
<thead>
<tr>
<th>Service</th>
<th>Revenue</th>
<th>Test Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hereditary cancer</td>
<td>(1%)</td>
<td>0%</td>
</tr>
<tr>
<td>Prenatal</td>
<td>42%</td>
<td>7%</td>
</tr>
<tr>
<td>Tumor profiling</td>
<td>94%</td>
<td>33%</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>103%</td>
<td>71%</td>
</tr>
<tr>
<td>Overall company</td>
<td>15%</td>
<td>15%</td>
</tr>
<tr>
<td>Overall company (excluding divestitures)</td>
<td>27%</td>
<td>20%</td>
</tr>
</tbody>
</table>